MLL-MLLT1 rearrangement, present in 2–3% of T-ALL, has a better outcome, whereas PICALM-MLLT10 rearrangement (about 6–7% of cases) is linked to worse prognosis (39, 89, 90). This evidence concerns the gene MLLT1 and acute lymphoblastic leukemia.